Why Cardinal Health’s Profit Outlook Matters More Than Its Revenue Miss
$Cardinal Health(CAH)$’s fiscal fourth quarter was not uniformly strong: revenue missed expectations, and its medical-products operation remained under pressure. Investors nevertheless focused on management’s above-consensus 2027 earnings forecast, which suggests pharmaceutical distribution, specialty care and home-health investments can keep expanding profit faster than sales.
Cardinal reported before the August 11 market open for the quarter ended June 30. Revenue increased 6% to $63.7 billion, below the roughly $65.2 billion expected. Adjusted earnings reached $2.91 per share, including a $0.31 benefit from a one-time tariff refund; excluding that item, adjusted earnings still increased 25% to $2.60. Cardinal Health’s official fourth-quarter release provides the divisional results and outlook.
The bullish thesis begins with scale. Cardinal distributes medicines and medical supplies across a network where reliability, regulatory controls and working capital create meaningful barriers to entry. Pharmaceutical revenue increased 6%, supported by higher volume from existing customers and favourable generic-drug performance. Specialty pharmaceuticals, cell-and-gene therapies and services for community oncology can produce better economics than conventional wholesale distribution.
Management forecast fiscal 2027 adjusted earnings of $12.40–$12.60 per share, representing 13%–15% growth and exceeding the market forecast near $12.08. Cardinal is also expanding its at-Home Solutions operation through acquisitions, including Strive Medical and AdaptHealth’s diabetes unit, giving it exposure to care shifting from hospitals into patients’ homes.
The bearish evidence is that parts of the quarter were temporarily flattered. The tariff refund added approximately $100 million to operating profit, while Medical Products and Distribution revenue declined 2% because of lower volumes. Drug distributors also operate on thin margins and depend on a small number of large customers. Acquisition spending creates integration and leverage risk, and reimbursement changes can affect specialty and home-care economics.
CAH Daily Chart
Cardinal gained 1.2% to $240.26 on August 11 after reaching $257.96 and falling as low as $235. The positive close is constructive, but the large reversal from the high shows that investors debated earnings quality. Approximately $235–$240 is initial support, while $250 followed by $258 is resistance.
The evidence leans moderately bullish because the underlying earnings growth and 2027 forecast outweigh the revenue miss. The view would be invalidated by pharmaceutical volume weakening, the medical division failing to recover, acquisitions diluting returns or adjusted earnings falling short after excluding temporary benefits. This is personal opinion for education and is not financial advice.
@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
